GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » Selling, General, & Admin. Expense

Paradigm Biopharmaceuticals (ASX:PAR) Selling, General, & Admin. Expense : A$5.52 Mil (TTM As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals Selling, General, & Admin. Expense?

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Paradigm Biopharmaceuticals's selling, general, & admin. expense for the six months ended in Dec. 2023 was A$3.52 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$5.52 Mil.


Paradigm Biopharmaceuticals Selling, General, & Admin. Expense Historical Data

The historical data trend for Paradigm Biopharmaceuticals's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals Selling, General, & Admin. Expense Chart

Paradigm Biopharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Selling, General, & Admin. Expense
Get a 7-Day Free Trial 2.32 4.17 8.75 7.93 6.57

Paradigm Biopharmaceuticals Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.78 4.15 4.56 2.00 3.52

Competitive Comparison of Paradigm Biopharmaceuticals's Selling, General, & Admin. Expense

For the Biotechnology subindustry, Paradigm Biopharmaceuticals's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paradigm Biopharmaceuticals's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paradigm Biopharmaceuticals's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Paradigm Biopharmaceuticals's Selling, General, & Admin. Expense falls into.



Paradigm Biopharmaceuticals Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$5.52 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Paradigm Biopharmaceuticals  (ASX:PAR) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Paradigm Biopharmaceuticals Selling, General, & Admin. Expense Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Paradigm Biopharmaceuticals (ASX:PAR) Business Description

Traded in Other Exchanges
Address
500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000
Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).